As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did descriptions of an associated coagulopathy and thrombotic complications . Hospitals created institutional protocols for inpatient management of COVID-19 coagulopathy and thrombosis in response to this developing data . We collected and analyzed protocols from 21 US academic medical centers developed between January and May 2020 . We found greatest consensus on recommendations for heparin-based pharmacologic venous thromboembolism (VTE) prophylaxis in COVID-19 patients without contraindications. Protocols differed regarding incorporation of D-dimer tests, dosing of VTE prophylaxis, indications for post-discharge pharmacologic VTE prophylaxis, how to evaluate for VTE, and the use of empiric therapeutic anticoagulation . These findings support ongoing efforts to establish international, evidence-based guidelines.